Browsing Tag
SARS-CoV-2
49 posts
Does host-pathway targeting offer a durable COVID-19 strategy for Bioxytran, Inc.?
Bioxytran, Inc. reports early ProLectin-M data. Explore what host-targeted antivirals mean for COVID-19 strategy and biotech investors.
Coronavirus is still evolving: The essential guide to symptoms, treatment options, and protection
Explore this complete guide on coronavirus symptoms, treatment options, and prevention tips to stay protected every year.
China discovers new bat coronavirus HKU5-CoV-2: How serious is the threat?
A newly identified bat coronavirus, HKU5-CoV-2, has been discovered by Chinese scientists, raising concerns about animal-to-human transmission and…
New SARS-CoV-2 variant BA.2.86 detected: UKHSA releases initial risk assessment amid global concerns
The UK Health Security Agency (UKHSA) has unveiled its preliminary risk analysis of the SARS-CoV-2 variant BA.2.86, a…
Nasodine Nasal Spray phase 3 clinical trial : Firebrick Pharma completes 82% patient recruitment
Firebrick Pharma, an ASX-listed pharmaceutical company, announced that it has successfully enrolled 160 subjects in the confirmatory phase…
Pfizer gets PAXLOVID FDA approval for COVID-19 in high-risk adults
Pfizer has obtained approval for PAXLOVID, an oral combination therapy of nirmatrelvir tablets and ritonavir tablets, from the…
AstraZeneca strikes licensing deal with RQ Bio for SARS-CoV-2 targeting mAbs
AstraZeneca has signed a licensing deal with RQ Biotechnology (RQ Bio) to gain access to a portfolio of…
AstraZeneca gets UK MHRA approval for Evusheld for Covid-19 prevention
AstraZeneca said that its antibody combination Evusheld (tixagevimab co-packaged with cilgavimab) has been authorized by the UK Medicines…
Torrent Pharmaceuticals gets rights to generic of Pfizer’s oral Covid-19 treatment
Torrent Pharmaceuticals has entered into a licensing agreement with Medicine Patent Pool (MPP) for manufacturing and commercializing the…
Sorrento Therapeutics acquires majority stake in Zhengzhou FortuneBio
Sorrento Therapeutics has acquired a majority stake in Zhengzhou Fortune Bioscience (Zhengzhou FortuneBio), a Chinese diagnostic manufacturer, for…